A comprehensive evaluation of the accuracy of cervical pre-cancer detection methods in a high-risk area in East Congo

British Journal of Cancer

Volumn 102, Issue 6, 2010, Pages 957-965

  Hovland, S ^a   Arbyn, M ^b   Lie, A K ^c   Ryd, W ^d   Borge, B ^c   Berle, E J ^e   Skomedal, H ^a   Kadima, T M ^f   Kyembwa, L ^f   Billay, E M ^f   Mukwege, D ^g   Chirimwami, R B ^h   Mvula, T M ^h   Snijders, P J ⁱ   Meijer, C J L M ⁱ   Karlsen, F ^a  

^a NorChip AS   (Norway)

^b SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^f Centre Hospitalier CELPA   (Norway)

^g Panzi Hospital   (Norway)

^h General Hospital   (Norway)

ⁱ VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Africa; CIN; E6 E7 mRNA; HPV DNA; PreTect HPV Proofer; RLB

Indexed keywords

ADULT; ARTICLE; CANCER DIAGNOSIS; COLPOSCOPY; CONGO; CYTOLOGY; FEMALE; HIGH RISK POPULATION; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; POLYMERASE CHAIN REACTION; PRECANCER; PRIORITY JOURNAL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIROLOGY;

EID: 77949542340     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605594     Document Type: Article

References (34)

1. Arbyn M, Hovland S (2006) Test characteristics of multiple cytological and HPV nucleic acid assays to detect high-grade CIN. A study on 343 women from South-Kivu (Democratic Republic of Congo). IPH/EPI-REPORTS 1: 1-60. Brussels
2. Arbyn M, Sankaranarayanan R, Muwonge R, Keita N, Dolo A, Mbalawa CG, Nouhou H, Sakande B, Wesley R, Somanathan T, Sharma A, Shastri S, Basu P (2008) Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India. Int J Cancer 123: 153-160
3. Baier T, Hansen-Hagge TE, Gransee R, Crombe A, Schmahl S, Paulus C, Drese KS, Keegan H, Martin C, O'Leary JJ, Furuberg L, Solli L, Grønn P, Falang IM, Karlgard A, Gulliksen A, Karlsen F (2009) Hands-free sample preparation platform for nucleic acid analysis. Lab on a Chip 9: 3399-3405
4. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der Noordaa J (1990) Rapid and simple method for purification of nucleic acids. J Clin Microbiol 28(3): 495-503
5. Bosch FX, de Sanjose S (2003) Chapter 1: human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr 2003(31): 3-13. Review
6. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV (2002) The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55(4): 244-265
7. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S (2003a) Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88: 63-73
8. Clifford GM, Smith JS, Aguado T, Franceschi S (2003b) Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 89(1): 101-105
9. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM (2005) Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 14(5): 1157-1164
10. Cuschieri KS, Cubie HA, Whitley MW, Gilkison G, Arends MJ, Graham C, McGoogan E (2005) Persistent High risk HPV infection associated with development of cervical neoplasia in a prospective population study. J Clin Pathol 58(9): 946-950
11. Cuschieri KS, Whitley MJ, Cubie HA (2004) HPV type specific DNA and RNA persistence-Implications for Cervical Disease Progression and Monitoring. J Med Virol 73(1): 65-70
12. Denny L, Kuhn L, De Souza M, Pollack AE, Dupree W, Wright Jr TC (2005) Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. JAMA 294(17): 2173-2181
13. Denny L, Kuhn L, Pollack A, Wainwright H, Wright TC (2000) Evaluation of alternative methods of cervical cancer screening for resource-poor setting. Cancer 89(4): 826-833
14. Gage JC, Hanson VW, Abbey K, Dippery S, Gardner S, Kubota J, Schiffman M, Solomon D, Jeronimo J, for The ASCUS LSIL Triage Study (ALTS) Group (2006) Number of Cervical Biopsies and Sensitivity of Colpo-scopy. Obstet Gynecol 108: 264-272
15. Goldie SJ, Freedberg KA, Weinstein MC, Wright TC, Kuntz KM (2001) Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus. Am J Med 111(2): 140-149
16. Gulliksen A, Solli LA, Drese KS, Sörensen O, Karlsen F, Rogne H, Hovig E, Sirevag R (2005) Parallel nanoliter detection of cancer markers using polymer microchips. Lab on a Chip 5: 416-420
17. International Agency for Research on Cancer (IARC) (2007) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. IARC Monographs Vol. 90, pp 191-192
18. Jacobs MV, Snijders PJF, van den Brule AJC, Helmerhorst TJM, Meijer CJLM, Walboomers JM (1997) A general primer GP5+/6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 35(3): 791-795
19. Jeronimo J, Schiffman M (2006) Colposcopy at crossroads. Am J Obstet Gynecol 195(2): 349-353
20. Kraus I, Molden T, Holm R, Lie AK, Kristensen F, Skomedal H (2006) Presence of E6 and E7 mRNA from human Papillomavirus 16, 18, 31, 33 and 45 in the majority of cervical Carcinomas. J Clin Microbiol 44(4): 1310-1317
21. Kurman RJ, Norris HJ, Wilkinson EJ (1992) Tumors of the Cervix. Scuamous Lesions. Tumors of the Cervix, Vagina and Vulva. Armed forces Institute of Pathology: Washington, DC, USA, p 37-77
22. Munoz N, Bosch FX, Castellsague X, D́iaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ (2004) Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111(2): 278-285
23. Parkin DM, Pisani P, Ferlay J (1999) Global cancer statistics. CA Cancer J Clin 49: 33-64
24. Qiao Y, Sellors JW, Eder PS, Bau Y, Lim JM, Zhao F, Weigl B, Zhang W, Peck RB, Li L, Chen F, Pan Q, Lorincz A (2008) A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncology 9: 929-936
25. Sangwa-Lugoma G, Mahmud S, Nasr SH, Liaras J, Kayembe PK, Tozin RR, Drouin P, Lorincz A, Ferenczy A, Franco EL (2006) Visual inspection as a cervical cancer screening method in a primary health care setting in Africa. Int J Cancer 119(6): 1389-1395
26. Schiffman M, Khan MJ, Solomon D, Herrero R, Wacholder S, Hildesheim A, Rodriguez AC, Bratti MC, Wheeler CM, Burk RD, PEG Group; ALTS Group (2005a) A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst 97(2): 147-150
27. Schiffman MA, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, Wright TC, Solomon D, Chen Z, Schussler J, Castle PE, Burk RD (2005b) The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 337(1): 76-84
28. Sellors J, Qiao Y, Bao Y, Ren S, Lim J, Zhao F, Zhang W, Pan Q, Fontaniere B, Frappart L (2005) False-negative colposcopy: quantifying the problem. In: Book of abstracts: 22nd International HPV Conference and Clinical Workshop 2005; 2005 April 30-May 6; Vancouver, B.C., Canada: UCSF; Poster Presentation P-490
29. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM (2007) Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121(3): 621-632
30. Snijders PJ, van den Brule AJ, Jacobs MV, Pol RP, Meijer CJLM (2005) HPV DNA detection and typing in cervical scrapes by general primer GP5+/6+ PCR. In Methods in Molecular Medicine: Human papillomaviruses-Methods and Protocols Davy CEDJE, Doorbar J (eds), pp 101-114. Humana Press: Totowa
31. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright Jr T, Young N, Forum Group Members; Bethesda 2001 Workshop (2002) The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 287(16): 2114-2119
32. van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ (2002) GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papilloma-virus genotypes. J Clin Microbiol 40(3): 779-787
33. Zhang C, Xing D (2007) Miniaturized PCR chips for nucleic acid amplification and analysis: latest advances and future trends. Nucleic Acids Res 35(13): 4223-4237
34. Zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2(5): 342-350. Review